Immunoglobulin A mucosal immunity in people with cystic fibrosis shortly after initiation of highly effective modulator therapy
Even with highly effective modulator therapy, the pIgR/IgA system remains hyperactivated after ≥3 months of treatment, suggesting that at this time the local IgA immunity is always impaired.
Authors
- Angélique Mottais (ORCID: https://orcid.org/0000-0002-3343-8872)
- Marylène Lecocq
- Antoine Froidure (ORCID: https://orcid.org/0000-0001-7133-1788)
- Sophie Gohy
- Christophe Goubau (ORCID: https://orcid.org/0000-0002-1631-398X)
- Charles Pilette (ORCID: https://orcid.org/0000-0001-6685-0356)
- Silvia Berardis (ORCID: https://orcid.org/0000-0002-2587-1019)
- Zhaojun Qiu (ORCID: https://orcid.org/0000-0001-8582-5068)
- Valérie Hox (ORCID: https://orcid.org/0000-0003-2390-294X)
- Bruno Detry
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- ERN GUARD-Heart (NL)
- UCLouvain (BE)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1183/23120541.01369-2024
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Université Catholique de Louvain
- Vertex Pharmaceuticals
- Fonds De La Recherche Scientifique - FNRS
- Cliniques Universitaires Saint-Luc